Vijaya Diagnostic Centre Ltd.
VIJAYAHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
19 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (1 of 19 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20211117 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220216 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220817 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221118 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230220 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230606 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230818 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231116 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240212 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240516 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240813 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241112 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250217 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250515 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250802 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251107 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260219 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260513 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260810 | 2026-06-30 | yes |
VIJAYA
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,526.50 |
| 52-week range | 861.4 – 1570.7 |
| Return 1M | 2.91% |
| Return 3M | 11.6% |
| Return 1Y | 45.08% |
| Return 3Y | 233.62% |
| Return 5Y | 163.3% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 231.00 |
| Other income | 9.00 |
| Total income | 240.00 |
| Cost of materials consumed | 26.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | 0.00 |
| Employee benefit expense | 37.00 |
| Finance costs | 11.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.52 | -0.00 |
| institutions foreign | 0.12 | -0.02 |
| institutions domestic | 0.32 | 0.02 |
| mutual funds | 0.31 | 0.02 |
| public | 0.48 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 19 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-06-30 | 2022-09-30 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 104.00 | 121.00 | 121.00 | 121.00 | 139.00 | 133.00 | 155.00 | 156.00 | 183.00 | 169.00 | 173.00 | 188.00 | 202.00 | 205.00 | 219.00 | 231.00 |
| Other income | 3.00 | 3.00 | 5.00 | 6.00 | 7.00 | 5.00 | 3.00 | 4.00 | 5.00 | 5.00 | 6.00 | 7.00 | 6.00 | 5.00 | 2.00 | 9.00 |
| Total income | 107.00 | 124.00 | 126.00 | 127.00 | 146.00 | 138.00 | 158.00 | 160.00 | 187.00 | 174.00 | 179.00 | 195.00 | 208.00 | 210.00 | 222.00 | 240.00 |
| Cost of materials consumed | 13.00 | 17.00 | 16.00 | 14.00 | 16.00 | 16.00 | 19.00 | 19.00 | 23.00 | 21.00 | 22.00 | 21.00 | 24.00 | 24.00 | 25.00 | 26.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Employee benefit expense | 19.00 | 20.00 | 20.00 | 21.00 | 22.00 | 23.00 | 25.00 | 27.00 | 28.00 | 29.00 | 28.00 | 32.00 | 32.00 | 33.00 | 34.00 | 37.00 |
| Finance costs | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 7.00 | 7.00 | 7.00 | 8.00 | 9.00 | 9.00 | 11.00 |
| Depreciation and amortisation | 14.00 | 16.00 | 11.00 | 12.00 | 14.00 | 15.00 | 16.00 | 17.00 | 17.00 | 18.00 | 19.00 | 21.00 | 22.00 | 24.00 | 24.00 | 25.00 |
| Other expenses | 32.00 | 36.00 | 37.00 | 38.00 | 43.00 | 41.00 | 49.00 | 49.00 | 56.00 | 52.00 | 54.00 | 61.00 | 63.00 | 62.00 | 65.00 | 69.00 |
| Total expenses | 83.00 | 93.00 | 89.00 | 91.00 | 101.00 | 101.00 | 115.00 | 118.00 | 130.00 | 127.00 | 130.00 | 143.00 | 150.00 | 152.00 | 158.00 | 169.00 |
| Profit before exceptional items and tax | 24.00 | 31.00 | 37.00 | 35.00 | 45.00 | 37.00 | 44.00 | 42.00 | 57.00 | 47.00 | 48.00 | 52.00 | 58.00 | 58.00 | 64.00 | 71.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 24.00 | 31.00 | 37.00 | 35.00 | 45.00 | 35.00 | 44.00 | 42.00 | 57.00 | 47.00 | 47.00 | 52.00 | 58.00 | 58.00 | 64.00 | 71.00 |
| Current tax | 7.00 | 7.00 | 8.00 | 7.00 | 9.00 | 9.00 | 8.00 | 10.00 | 13.00 | 9.00 | 9.00 | 12.00 | 13.00 | 12.00 | 15.00 | 17.00 |
| Deferred tax | -1.00 | 1.00 | 1.00 | 2.00 | 2.00 | -0.00 | 2.00 | 1.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 1.00 |
| Tax expense | 6.00 | 8.00 | 9.00 | 9.00 | 11.00 | 9.00 | 10.00 | 10.00 | 15.00 | 11.00 | 13.00 | 14.00 | 15.00 | 15.00 | 16.00 | 18.00 |
| Profit for the period | 18.00 | 23.00 | 28.00 | 26.00 | 34.00 | 26.00 | 34.00 | 32.00 | 42.00 | 35.00 | 35.00 | 39.00 | 43.00 | 43.00 | 48.00 | 53.00 |
| Profit attributable to owners | 17.00 | 23.00 | 27.00 | 26.00 | 33.00 | 26.00 | 33.00 | 31.00 | 42.00 | 35.00 | 35.00 | 38.00 | 43.00 | 43.00 | 48.00 | 53.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | -0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Total comprehensive income | 18.00 | 24.00 | 28.00 | 26.00 | 34.00 | 26.00 | 33.00 | 31.00 | 42.00 | 35.00 | 35.00 | 39.00 | 44.00 | 43.00 | 48.00 | 53.00 |
| Earnings per share, basic | 1.71 | 2.29 | 2.69 | 2.57 | 3.26 | 2.53 | 3.27 | 3.06 | 4.09 | 3.42 | 3.38 | 3.76 | 4.21 | 4.20 | 4.66 | 5.16 |
| Earnings per share, diluted | 1.70 | 2.27 | 2.68 | 2.56 | 3.25 | 2.52 | 3.26 | 3.05 | 4.08 | 3.42 | 3.37 | 3.75 | 4.20 | 4.19 | 4.65 | 5.15 |
Annual results, as filed
| Line | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|
| Revenue from operations | 462.00 | 459.00 | 548.00 | 681.00 | 814.00 |
| Other income | 13.00 | 14.00 | 21.00 | 18.00 | 21.00 |
| Total income | 475.00 | 473.00 | 569.00 | 700.00 | 835.00 |
| Cost of materials consumed | 71.00 | 59.00 | 65.00 | 85.00 | 95.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Employee benefit expense | 71.00 | 78.00 | 90.00 | 112.00 | 131.00 |
| Finance costs | 16.00 | 21.00 | 24.00 | 27.00 | 33.00 |
| Depreciation and amortisation | 53.00 | 62.00 | 57.00 | 71.00 | 92.00 |
| Other expenses | 117.00 | 140.00 | 171.00 | 211.00 | 252.00 |
| Total expenses | 328.00 | 360.00 | 408.00 | 506.00 | 602.00 |
| Profit before exceptional items and tax | 147.00 | 114.00 | 161.00 | 194.00 | 233.00 |
| Exceptional items | 0.00 | 0.00 | -2.00 | -1.00 | 0.00 |
| Profit before tax | 147.00 | 114.00 | 159.00 | 193.00 | 233.00 |
| Current tax | 40.00 | 28.00 | 33.00 | 41.00 | 51.00 |
| Deferred tax | -3.00 | 1.00 | 6.00 | 8.00 | 9.00 |
| Tax expense | 37.00 | 28.00 | 39.00 | 49.00 | 60.00 |
| Profit for the period | 111.00 | 85.00 | 120.00 | 144.00 | 173.00 |
| Profit attributable to owners | 110.00 | 85.00 | 119.00 | 143.00 | 173.00 |
| Profit attributable to non-controlling interests | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
| Other comprehensive income | 0.00 | 0.00 | -0.00 | 0.00 | 1.00 |
| Total comprehensive income | 111.00 | 85.00 | 120.00 | 144.00 | 174.00 |
| Earnings per share, basic | 10.76 | 8.29 | 11.62 | 13.95 | 16.81 |
| Earnings per share, diluted | 10.69 | 8.26 | 11.59 | 13.92 | 16.79 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 799.00 | 853.00 | 926.00 | 983.00 | 1,125.00 | 1,274.00 | 1,391.00 | 1,507.00 |
| Non-current assets | 527.00 | 578.00 | 608.00 | 771.00 | 851.00 | 966.00 | 1,070.00 | 1,185.00 |
| Current assets | 272.00 | 276.00 | 319.00 | 211.00 | 275.00 | 307.00 | 320.00 | 322.00 |
| Property, plant and equipment | 479.00 | 294.00 | 561.00 | 602.00 | 664.00 | 724.00 | 843.00 | 930.00 |
| Capital work-in-progress | 9.00 | 249.00 | 15.00 | 8.00 | 18.00 | 70.00 | 45.00 | 34.00 |
| Goodwill | 5.00 | 5.00 | 5.00 | 119.00 | 119.00 | 119.00 | 119.00 | 119.00 |
| Other intangible assets | 2.00 | 2.00 | 4.00 | 21.00 | 20.00 | 22.00 | 21.00 | 20.00 |
| Inventories | 5.00 | 2.00 | 4.00 | 5.00 | 7.00 | 5.00 | 4.00 | 5.00 |
| Trade receivables | 9.00 | 9.00 | 10.00 | 16.00 | 13.00 | 15.00 | 12.00 | 21.00 |
| Cash and cash equivalents | 19.00 | 24.00 | 23.00 | 22.00 | 15.00 | 13.00 | 24.00 | 40.00 |
| Total equity and liabilities | 799.00 | 853.00 | 926.00 | 983.00 | 1,125.00 | 1,274.00 | 1,391.00 | 1,507.00 |
| Equity | 502.00 | 547.00 | 599.00 | 660.00 | 728.00 | 799.00 | 865.00 | 957.00 |
| Equity share capital | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Other equity | 490.00 | 535.00 | 587.00 | 647.00 | 715.00 | 785.00 | 855.00 | 947.00 |
| Total liabilities | 298.00 | 307.00 | 327.00 | 323.00 | 397.00 | 474.00 | 526.00 | 550.00 |
| Non-current liabilities | 224.00 | 241.00 | 248.00 | 250.00 | 281.00 | 312.00 | 365.00 | 426.00 |
| Current liabilities | 73.00 | 66.00 | 79.00 | 73.00 | 116.00 | 163.00 | 160.00 | 124.00 |
| Borrowings, non-current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Borrowings, current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Trade payables | 29.00 | 28.00 | 33.00 | 33.00 | 38.00 | 33.00 | 40.00 | 38.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 86.00 | 165.00 | 95.00 | 183.00 | 125.00 | 224.00 | 139.00 | 271.00 |
| Net cash from investing activities | -64.00 | -110.00 | -80.00 | -142.00 | -105.00 | -182.00 | -84.00 | -174.00 |
| Net cash from financing activities | -14.00 | -42.00 | -16.00 | -45.00 | -28.00 | -52.00 | -43.00 | -69.00 |
| Purchase of property, plant and equipment | 73.00 | 125.00 | 50.00 | 88.00 | 40.00 | 96.00 | 93.00 | 183.00 |
| Net increase in cash | 8.00 | 13.00 | -1.00 | -4.00 | -8.00 | -9.00 | 11.00 | 27.00 |
| con:CFO.BEFORE_TAX | 97.00 | 191.00 | 110.00 | 217.00 | 145.00 | 264.00 | 160.00 | 323.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 11.00 | 26.00 | 15.00 | 34.00 | 20.00 | 40.00 | 21.00 | 52.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 80.00 | 49.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 3.00 | 0.00 | 3.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 148.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2022-12-31 | 2023-03-31 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 55.01 | 55.01 | 54.90 | 54.87 | 54.06 | 53.93 | 53.91 | 53.91 | 53.05 | 52.63 | 0.53 | 0.53 | 0.53 | 0.52 |
| Domestic institutions | 14.23 | 13.90 | 18.64 | 19.83 | 20.80 | 21.49 | 23.46 | 24.63 | 23.72 | 24.07 | 0.25 | 0.29 | 0.30 | 0.32 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 23.55 | 0.25 | 0.28 | 0.29 | 0.31 |
| Insurance companies | 0.00 | 0.00 | 0.00 | 0.14 | 0.21 | 0.44 | 0.50 | 0.55 | 0.01 | 0.48 | 0.01 | 0.01 | 0.01 | 0.01 |
| Foreign institutions | 24.96 | 25.28 | 20.68 | 19.95 | 20.09 | 20.08 | 18.14 | 17.54 | 19.36 | 19.56 | 0.18 | 0.15 | 0.13 | 0.12 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Public | 44.99 | 44.99 | 45.10 | 45.13 | 45.94 | 46.07 | 46.09 | 46.09 | 46.95 | 47.37 | 0.47 | 0.47 | 0.47 | 0.48 |
| Non-institutional | 5.80 | 5.81 | 5.78 | 5.35 | 5.05 | 4.50 | 4.49 | 3.92 | 3.87 | 3.74 | 0.04 | 0.04 | 0.04 | 0.04 |
| Shares outstanding | 102069262 | 102071175 | 102267482 | 102308639 | 102345693 | 102597450 | 102622270 | 102629462 | 102636278 | 102687111 | 102724936 | 102724936 | 102896728 | 102988473 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Dr. S Surendranath Reddy | Executive Director - Chairman | Any other transaction, Remuneration | 37,580,000.00 | 3 |
| P H Diagnostic Centre Private Limited | Wholly-Owned Subsidiary | Interest received, Investment, Loan, Sale of fixed a | 36,781,000.00 | 5 |
| Narasimha Raju K.A. | Key Management Personnel | Any other transaction, Remuneration | 36,080,000.00 | 2 |
| S Geeta Reddy | Non-Executive Director | Any other transaction | 22,826,000.00 | 4 |
| S Suprita Reddy | Managing Director & CEO | Any other transaction, Remuneration | 19,260,000.00 | 3 |
| K Sunil Chandra | Executive Director | Any other transaction, Remuneration | 10,676,000.00 | 3 |
| Medinova Diagnostics Services Limited | Subsidiary | Any other transaction, Interest received, Purchase o | 7,390,000.00 | 6 |
| Vijaya Hospitals Private Limited | Enterprise where Directors have si | Any other transaction | 6,253,000.00 | 2 |
| Hansraj Singh | Key Management Personnel | Any other transaction, Remuneration | 4,187,000.00 | 2 |
| Park Health Systems Private Limited | Relative of Director having signif | Sale of goods or services | 3,872,000.00 | 1 |
| Medinova Millennium MRI Services LLP | Subsidiary | Any other transaction, Purchase of goods or services | 767,000.00 | 2 |
| Dr. D. Nageshwar Reddy | Independent Director | Remuneration | 600,000.00 | 1 |
| Mr. S P Singh | Independent Director | Remuneration | 600,000.00 | 1 |
| Satyanarayana Murthy Chavali | Independent Director | Remuneration | 600,000.00 | 1 |
| Dr. Manjula Anagani | Independent Director | Remuneration | 600,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-10 | Q1FY27 | Read the call | |
| 2026-05-13 | Q4FY26 | Read the call | |
| 2026-02-19 | Q3FY26 | Read the call | |
| 2025-11-07 | Q2FY26 | INVESTOR, SECURITIES LIMITED, VIJAYA | Read the call |
| 2025-08-02 | Q1FY26 | DIAGNOSTIC CENTER LIMITED, SECURITIES LIMITED | Read the call |
| 2025-05-15 | Q4FY25 | Read the call | |
| 2025-02-17 | Q3FY25 | CENTRE LIMITED | Read the call |
| 2024-11-12 | Q2FY25 | Read the call | |
| 2024-08-13 | Q1FY25 | VIJAYA DIAGNOSTIC CENTRE LIMITED | Read the call |
| 2024-05-16 | Q4FY24 | Read the call | |
| 2024-02-12 | Q3FY24 | EXECUTIVE, VIJAYA DIAGNOSTIC CENTRE | Read the call |
| 2023-11-16 | Q2FY24 | DIAGNOSTIC CENTRE LIMITED, LIMITED, VIJAYA DIAGNOSTIC CENTRE LIMITED | Read the call |
| 2023-08-18 | Q1FY24 | Read the call | |
| 2023-06-06 | Q4FY23 | Read the call | |
| 2023-02-20 | Q3FY23 | Read the call | |
| 2022-11-18 | Q2FY23 | Read the call | |
| 2022-08-17 | Q1FY23 | Read the call | |
| 2022-02-16 | Q3FY22 | Read the call | |
| 2021-11-17 | Q2FY22 | CENTRE LIMITED, DIAGNOSTIC CENTRE LIMITED, VIJAYA DIAGNOSTIC CENTRE LIMITED | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY23 | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | So, if you see the maximum CAPEX that we deployed happened during some Q3 of FY'22 to FY'23 that is like last one year. | So what is the plan here in terms of what is the nature of hubs that we are going to open and how would this stand vis-à-vis our Kolkata hub in terms … | Raju sir, does this materially alter our capex plans for the next 1, 1.5 years, apart from the 2 hub additions that we are planning, the PET-CT machin… | Coming to the update on capital investment in the current period, we have largely utilized our capex plan for FY '26 with an overall capex outlay of I… | As you know, in the current year, we have added many centres, like almost close to like five hubs, with state-of-the-art facilities where a large cape… | So from an accounting perspective, when you take a projection, you might not consider a future capex, future revenue potential of these centers. | So my question is, as we see hub additions, so what's your capex plans in FY '26? | And in terms of capex for investment per annum, we have seen obviously in the recent years because of our geographical diversification, some capex int… |
| Capital allocation | — | Second question from my side is on the Pune acquisition. | I believe in Pune, we had an inorganic we had an acquisition and then we took almost 10, 11 months to start up the first spoke. | — | The second thing is on the inorganic acquisition side, how is the market presently? | Sir, just first question on this PH acquisition. | — | Anshul, like we've mentioned earlier, anything that comes to us in terms of an inorganic or a merger and acquisition, JV, whatever it might be, if it … |
| Costs | Anubhav Sahu I got it, I think largely it compensates for the input cost pressure. | — | — | — | So, across the industry, I think most people are basically saying that we cannot absorb some of those input costs, input increases, so they are really… | Until and unless, we see a significant increase in price and input costs, we do not pass it on to the customers. | Some value has increased because of the increase in the input cost. | — |
| Debt and cash | — | So, just trying to understand, is there some sort of over testing that happened in the wellness segment last year and that's the base effect that's co… | — | — | — | And so the rest would be towards working capital on the gross lock. | — | So practically, what is the thought process here because obviously, the cash flow comes in operation if you see, has been obviously becoming stronger … |
| Demand | Cyndrella Carvalho And coming to the non-Hyderabad market, how are we seeing this, is there any update in terms of demand, are we seeing the same kind… | So the 15 centers probably are in pipeline. but due to some delays from the lesser than the landlords, probably they would not be able to come in this… | So there's a lot of demand, but you don't have a single large player. | This highlights the strong demand for quality integrated diagnostic services in the region. | — | Just wanted to ask that the demand generation is similar. | — | But let's say, like we also said there are more hubs in pipeline. |
| Guidance | And are you still maintaining your revenue guidance of 14% to 15%? | So, what we expect that is irrespective to the geography, the growth will be driven mainly because of the volume growth. | And Ongole, can we expect that to break even this quarter or next quarter? | Our two new hubs are ramping up steadily and are on track to reach breakeven within one year, in line with our guidance. | I think the guidance does not change like we've been saying that the strategy is to open those 15 centres. | Sure, and do we expect to grow at similar double-digit rate in the core regions over the next 2 years? | So, we expect there will be increase in the cost not just for the rupee depreciation but for multiple other reasons that's happening in the internatio… | So, this is a capex guidance for the executed leases, which is the 4 to 5 hubs and the 10 to 12 spokes. |
| Margin | And if you look at the performance of the centre that we opened in the Q1, whatever centres that we opened, it’s like six months old right now, so all… | So due to which the margin slightly dropped from 41% levels to 39.4% or 39.5%. | Even if you consider a 5% increase, it will come to like a 0.3% impact on the EBITDA side. | EBITDA for the current quarter stood at ~INR 86 crores as compared to ~INR 67 crores in the corresponding quarter in the previous year, reflecting a Y… | Sir, also about EBITDA margin, will it sustain? | What will be your thought process going ahead with the margin? | And generally, wellness -whenever wellness grows, you see some contraction in gross margin, right, because this wellness is at a discounted price. | So, my first question would be like in Q4, the EBITDA margin came in 43.5%, which is 380 bps Y-o-Y expansion. |
| People | So, in the last one year what are new specialties have we entered into and what hiring’s have we done in this super specialist, radiologist based on, … | — | — | — | — | — | In the earlier quarters, it was about INR 39 crores to INR 40 crores, but because of the incremental cost on hiring of new talent for these new upcomi… | — |
| Pricing | Prakash Kapadia And you see changes in competitive landscape or pricing which we have seen, is it gone worse, is it better, is it same from a competit… | Could you tell the reason for this or are we not really taking price hike and how should I be looking at the ARPP numbers going forward. | — | Are there any changes in their behavior in terms of pricing discounts, etc? | Sir, and this recent price increase which you have taken, on what portion of the portfolio would you have taken these price increases? | If you see, we did not do any price increase in the last year, hardly 1%, 2% is the price impact, right, and if you actually see on the other slide wh… | And the pricing is more like Hyderabad and definitely not like Pune or West Bengal. | The pricing is taken into consideration, keeping the entire Capex of the hospital in mind. |
| Revenue growth | So, see at a quarter level if you take 3 year CAGR on non-COVID revenue, we are roughly around 8.5%, but the encouraging thing is that if you actually… | So like you rightly said, out of this 18% 17% of the non-COVID revenue growth was driven by the parent company and only 1% of it coming from PH. | So, ma'am, in terms of the growth outlook, which we provided for the business from a 3-year perspective, in terms of 13% volume growth and 2% realizat… | I would like to congratulate the entire team for delivering robust performance across both the top line and the bottom line. | So, without investing further, we can give you a growth of maybe 10% to 11% with the existing network. | So, like we always say, we are confident that 1%, 2% whatever revenue growth that you see, right, 1%, 2% will be a price impact or the case mix. | So, coming to the growth of the industry, again, different research reports gives different numbers. | While we may have that 1% - 1.5% of realization growth, but the major focus for the next 2 to 3 years is capacity addition and volume-driven revenue g… |